Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 10/20 | 0.38 |
| ▸ | PDCD1 | Q15116 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | PDCD1LG2 | Q9BQ51 | 2/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphine SCHEMBL1716795 | 0.81 | — | — | |
| Methyl Alcohol SCHEMBL28032140 | 0.78 | — | — | |
| SCHEMBL22866559 | 0.76 | CD274 (0.61) | CD274PDCD1LOXL2TAAR1 | |
| SCHEMBL28747346 | 0.76 | CD274 (0.43) | CYP3A4TSHRPIK3CACD274PDCD1 | |
| Ethylamine SCHEMBL28797899 | 0.74 | CYP3A4 (0.78) | CYP3A4TSHRPIK3CAPOLBALDH1A1 | |
| SCHEMBL22434026 | 0.72 | ALDH1A1 (0.68) | CYP3A4TSHRPIK3CAPOLBALDH1A1 | |
| 1-Pentanol SCHEMBL28312242 | 0.71 | SMN1; SMN2 (0.52) | TSHRCD274PDCD1PDCD1LG2ALDH1A1 | |
| SCHEMBL3805255 | 0.71 | DPP4 (0.55) | CD274PDCD1HTR7PDCD1LG2LOXL2 | |
| SCHEMBL2206282 | 0.71 | CYP3A4 (0.72) | CYP3A4TSHRPIK3CAPOLBALDH1A1 | |
| SCHEMBL30839749 | 0.71 | CYP3A4 (0.72) | CYP3A4TSHRPIK3CAPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130164260-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130164260-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | CYP3A4 2443/4885TSHR 4860/4885PIK3CA 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.